Pain
From the Journals
Infusion centers may best EDs for treating sickle cell crises
At infusion centers, patients received pain medication an average of 70 minutes faster compared with patients treated in EDs.
Latest News
Opioid prescriptions decrease in young kids, long dosages increase
Researchers found reduced rates of high-dosage and long-duration prescriptions for adolescents and younger adults; however, these type of...
Conference Coverage
Novel NSAID–triptan drug effectively relieves migraine pain
About 74% of patients who received AXS-07 experienced no progression of pain from 2 to 24 hours.
Conference Coverage
Diaphragmatic endometriosis diagnosed many years after symptom onset
A survey of people who received surgery for diaphragmatic endometriosis finds it takes an average of five primary care visits before referral to a...
Photo Rounds
Foot rash and joint pain
An untreated infection led to a series of unusual signs and symptoms that included difficulty walking.
Conference Coverage
Photobiomodulation: Evaluation in a wide range of medical specialties underway
The therapy is used to treat a wide variety of medical and aesthetic disorders including acne vulgaris, psoriasis, burns, and wound healing.
Conference Coverage
Chronic headache pain in veterans linked to suicide attempts
U.S. veterans with chronic headache pain had an increased risk of attempting suicide compared with vets with chronic neck or back pain,...
Conference Coverage
e-TNS device passes at-home test
A phase 3 study showed the Cefaly device was particularly effective against most bothersome migraine symptoms.
Conference Coverage
A large proportion of migraine patients are not offered preventive treatment
Among patients eligible for preventive therapy, more than a third were not offered this option, fewer than 10% were currently taking preventive...
Feature
Physician convicted in buprenorphine scheme faces up to 20 years in prison
The West Virgina Board of Medicine suspended the license of Sriramloo Kesari, MD, 78, in February 2020.
Conference Coverage
Combination therapy may benefit patients with migraine
A retrospective chart review suggests adding an anti-CGRP antibody to onabotulinumtoxinA boosts benefit.